Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Epix Pharmaceuticals Inc. Stories

2011-11-29 12:11:00

WELLESLEY HILLS, Mass., Nov. 29, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG 277 discriminates against S1P3 receptor by 50-fold and that the S1P1 lead compounds will be offered December 8, 2011 in a sealed bid sale. These assets were generated by Epix Pharmaceuticals, Inc. and Amgen. AMG 277 has 57-nM functional EC50 for hS1P1 receptor and discriminates against...

2011-11-17 11:22:00

WELLESLEY HILLS, Mass., Nov. 17, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG 369 discriminates against S1P3 receptor by 296-fold and that the S1P1 lead compounds, including AMG 369, will be offered December 8, 2011 in a sealed bid sale. AMG 369 has 3-nM functional EC50 for hS1P1 receptor and discriminated against S1P3 receptor by 296-fold. It displayed efficacy in a DTH...

2011-11-08 15:25:00

WELLESLEY HILLS, Mass., Nov. 8, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, assets generated by Epix Pharmaceuticals, Inc. and Amgen, will be offered December 8, 2011 in a sealed bid sale. Target rationale for S1P1 agonists explained. The sphingosine-1-phosphate receptor 1 (S1P1) is one of a family of five G-protein-coupled receptors and is expressed...

2011-11-01 13:54:00

WELLESLEY HILLS, Mass., Nov. 1, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the back-up compounds and S1P1 lead compounds, assets generated by Epix Pharmaceuticals, Inc. and Amgen, will be offered December 8, 2011 in a sealed bid sale. Back-up Compounds -- A total of ~640 analogs were synthesized by Epix and/or Amgen chemists to explore the SAR of several chemical series...

2011-10-25 12:59:00

WELLESLEY HILLS, Mass., Oct. 25, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") revealed today the contractual agreements for S1P1 lead compounds, AMG 369 and AMG 277, offered December 8, 2011 in a sealed bid sale. AMG-369, AMG-277 and the six back-up compounds were discovered and/or developed as part of License Agreement between Amgen and Epix (formerly Predix) using technology that Epix licensed...

2011-10-18 10:33:00

WELLESLEY HILLS, Mass., Oct. 18, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, AMG 369 and AMG 277, will be offered December 8, 2011 in a sealed bid sale. S1P1 agonists are currently indicated for treatment of multiple sclerosis ("MS"). MS is the second most common cause of disability in young adults (after trauma) and affects approximately 350,000 -...

2011-10-06 14:11:00

WELLESLEY HILLS, Mass., Oct. 6, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 agonists program assets generated by Epix Pharmaceuticals, Inc. and Amgen will be offered December 8, 2011 in a sealed bid sale. S1P1 agonists are currently indicated for the treatment of multiple sclerosis. S1P1 agonists may also have significant potential in multiple other indications,...

2010-05-21 11:55:00

WELLESLEY HILLS, Mass., May 21 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the auction of the MRI imaging intellectual properties has been changed to June 22, 2010 at 9:00 A.M. Eastern. This was done to allow bidders to complete due diligence on all three (3) gadolinium-based imaging programs. They consist of 1) MS-325 (gadofosveset trisodium), commercial MRA imaging agent,...

2010-05-17 11:48:00

WELLESLEY HILLS, Mass., May 17 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the MRI imaging intellectual properties of the EP-3600 MRI imaging agent, which will be auctioned on May 28, 2010, include potential royalties of 2% each from the development and commercialization of three additional programs related to MRI imaging agents and/or technologies. There is also a fourth program...

2010-05-10 11:57:00

WELLESLEY HILLS, Mass., May 10 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the MRI imaging intellectual properties of the EP-2104R MRI imaging agent, which will be auctioned on May 28, 2010, include potential revenue sharing from the first commercial sale of non-MRI imaging agents developed and/or sold by a third party using the same proprietary technology that resulted in the...